-
1
-
-
0037382455
-
Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus
-
Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc. 2003 ; 78: 447-456
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 447-456
-
-
Gerich, J.E.1
-
2
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 diabetes
-
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
-
(2008)
N Engl J Med
, vol.358
, pp. 2545-2559
-
-
-
3
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
-
4
-
-
0036072223
-
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
-
Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002 ; 87: 2784-2791
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 2784-2791
-
-
Miyazaki, Y.1
Mahankali, A.2
Matsuda, M.3
-
5
-
-
10744225126
-
Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect
-
Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003 ; 26: 2493-2499
-
(2003)
Diabetes Care
, vol.26
, pp. 2493-2499
-
-
Satoh, N.1
Ogawa, Y.2
Usui, T.3
-
6
-
-
34250347668
-
Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trials
-
Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007 ; 154: 14-50
-
(2007)
Am Heart J
, vol.154
, pp. 14-50
-
-
Rosmarakis, E.S.1
Falagas, M.E.2
-
7
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomized controlled trial
-
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005 ; 366: 1279-1289
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
8
-
-
41649084422
-
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
-
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008 ; 299: 1561-1573
-
(2008)
JAMA
, vol.299
, pp. 1561-1573
-
-
Nissen, S.E.1
Nicholls, S.J.2
Wolski, K.3
-
9
-
-
73749087583
-
Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: A randomized prospective study using intravascular ultrasound
-
Nakayama T, Komiyama N, Yokoyama M, et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010 ; 138: 157-165
-
(2010)
Int J Cardiol
, vol.138
, pp. 157-165
-
-
Nakayama, T.1
Komiyama, N.2
Yokoyama, M.3
-
10
-
-
22644438570
-
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
-
Karter AJ, Ahmed AT, Liu H, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005 ; 22: 986-993
-
(2005)
Diabet Med
, vol.22
, pp. 986-993
-
-
Karter, A.J.1
Ahmed, A.T.2
Liu, H.3
-
11
-
-
0042383369
-
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone
-
Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab. 2003 ; 88: 3993-3996
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 3993-3996
-
-
Ogawa, S.1
Takeuchi, K.2
Ito, S.3
-
12
-
-
22344445087
-
Relationship between plasma hANP level and pretibial edema by pioglitazone treatment
-
Kahara T, Takamura T, Misaki T, et al. Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. Endocrine J. 2005 ; 52: 373-376
-
(2005)
Endocrine J
, vol.52
, pp. 373-376
-
-
Kahara, T.1
Takamura, T.2
Misaki, T.3
-
13
-
-
39049116452
-
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes
-
Sambanis C, Tziomalos K, Kountana E, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol. 2008 ; 45: 23-30
-
(2008)
Acta Diabetol
, vol.45
, pp. 23-30
-
-
Sambanis, C.1
Tziomalos, K.2
Kountana, E.3
-
14
-
-
1542652476
-
Thiazolidines, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications
-
Mudaliar S, Chang AR, Henry RR. Thiazolidines, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003 ; 9: 406-416
-
(2003)
Endocr Pract
, vol.9
, pp. 406-416
-
-
Mudaliar, S.1
Chang, A.R.2
Henry, R.R.3
-
15
-
-
0346219290
-
Considerations for management of fluid dynamic issues associated with thiazolidinediones
-
Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 2003 ; 115: 111S - 115S
-
(2003)
Am J Med
, vol.115
-
-
Hollenberg, N.K.1
-
16
-
-
0035668546
-
The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein- depleted plasma (FER(HDL))
-
Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001 ; 34: 583-588
-
(2001)
Clin Biochem
, vol.34
, pp. 583-588
-
-
Dobiasova, M.1
Frohlich, J.2
-
17
-
-
79953193064
-
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography
-
Dobiasova M, Frohlich J, Sedova M, et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011 ; 52: 566-571
-
(2011)
J Lipid Res
, vol.52
, pp. 566-571
-
-
Dobiasova, M.1
Frohlich, J.2
Sedova, M.3
-
18
-
-
0028340551
-
Stability of human atrial natriuretic peptide in blood samples
-
Tsuji T, Masuda H, Imagawa K, et al. Stability of human atrial natriuretic peptide in blood samples. Clin Chim Acta. 1994 ; 225: 171-177
-
(1994)
Clin Chim Acta
, vol.225
, pp. 171-177
-
-
Tsuji, T.1
Masuda, H.2
Imagawa, K.3
-
19
-
-
1642302410
-
Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men
-
Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004 ; 89: 1140-1145
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 1140-1145
-
-
Zanchi, A.1
Chiolero, A.2
Maillard, M.3
|